
FuseBio: Innovating immune-modulating therapeutics for cancer treatment.
Fuse Biotherapeutics, founded with a mission to revolutionize cancer treatment, focuses on developing innovative immune-modulating therapeutics. The company aims to harness the power of the immune system to create transformative therapies for cancer patients. By leveraging cutting-edge biotechnology, Fuse Biotherapeutics is dedicated to providing novel solutions that improve patient outcomes and address unmet medical needs in oncology.
Notable figures associated with Fuse Biotherapeutics include leading experts in biotechnology and oncology, though specific names are not publicly disclosed. The company has garnered attention for its pioneering approach and potential impact on cancer treatment. While still in its early stages, Fuse Biotherapeutics has made significant strides in research and development, positioning itself as a promising player in the biotech industry.

Duet BioTherapeutics

LTZ Therapeutics

Modifi Bio
modifibio.com

PineTree Therapeutics
pinetreetx.com

Window Therapeutics
windowtx.com

Bolt Biotherapeutics
boltbio.com

Umoja Biopharma

Faze Medicines
fazemed.com

Palm Therapeutics

Seneca Therapeutics

Modulus Therapeutics

Engage Bio

Thunder Biotech
thunderbiotech.com

Vibe Bio
vibebio.com

INmune Bio
inmunebio.com
Companies similar to Fuse Biotherapeutics include Duet BioTherapeutics, LTZ Therapeutics, Modifi Bio and PineTree Therapeutics.
Fuse Biotherapeutics was founded in 2021.
Fuse Biotherapeutics' headquarters is located in Los Angeles, CA, US.
Fuse Biotherapeutics' most recent funding round was for $9.5M (USD) in November 2021.
As of Nov 15, 2021, Fuse Biotherapeutics has raised a total of $9.5M (USD).
Fuse Biotherapeutics has 5 employees as of Feb 5, 2024.